| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -18.7 | -12.8 |
| EPS (diluted, $ a share) | $-0.49 | $-0.45 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CTNM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Contineum Therapeutics, Inc.: key numbers
- Share price
- $9.55Close, Nov 17
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Contineum Therapeutics, Inc.
All →Contineum Therapeutics Financial Results
Contineum Therapeutics reported third-quarter 2026 financial results, highlighting a net loss of $18.7 million and a cash position of $244.5 million. The company noted that its current capital resources are sufficient to fund operations through mid-2029, providing runway past the estimated completion of its Phase 2 PROPEL-IPF clinical trial. Research and development expenses increased 45% year-over-year to $16.0 million, primarily driven by the PIPE-791 program.
“Lysophosphatidic acid 1 receptor (LPAR1) antagonism as a treatment approach for pulmonary fibrosis has exceptionally strong clinical validation with multiple trials successfully completed including more than 1,600 patients. We believe the LPAR1 class can be the ideal backbone for combination treatments. Our LPAR1 antagonist, PIPE-791, is potentially differentiated in key ways including a favorable safety and tolerability profile, sustained target engagement which we believe has the potential for improved efficacy, and superior convenience in a one-time daily, low oral dose with no titration required for patients.”
Carmine Stengone, CEO, Contineum Therapeutics
“We continue to expand our footprint for PROPEL-IPF, with over 100 sites now online in 16 countries to facilitate a steady pace of enrollment. With a projected cash runway that extends through mid-2029, we are well positioned with capital resources one year past the estimated completion of our idiopathic pulmonary fibrosis (IPF) trial.”
Carmine Stengone, CEO, Contineum Therapeutics
Contineum Therapeutics Clinical Trial Data
Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for major depressive disorder did not meet its primary efficacy endpoint of improvement in the MADRS total score. The drug candidate, which is being developed under a global license agreement with Johnson & Johnson, was well-tolerated with no new safety signals. Johnson & Johnson is currently evaluating the full data set, including exploratory endpoints, to determine the next steps for the program.
- Counterparty
- Johnson & Johnson